Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPER-6: PF-08653944 Once-Monthly in Adults With Overweight or Obesity
jRCT2051260113Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight, type 2 diabetes mellitus (T2DM) and 4 more comparing PF-08653944 once-monthly with Placebo once-monthly (2 arms). Primary endpoint: Percent change from baseline in body weight. Started Aug 2026; status: recruiting.
02
Drugs
PF-08653944
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on jRCT2051260113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260113.